Samsung Biologics Secures Record-Breaking $1.24 Billion Manufacturing Deal with Asian Pharma Giant
In a major coup for the company, Samsung Biologics, a global leader in contract development and manufacturing (CDMO), has announced a groundbreaking agreement with a leading Asian pharmaceutical company. The deal, valued at a staggering $1.24 billion, represents the largest single client contract ever signed by Samsung Biologics. This strategic partnership signifies a significant milestone for the company, further solidifying its position as a dominant force in the biopharmaceutical manufacturing landscape.
Production for this monumental agreement will take place at Samsung Biologics’ state-of-the-art biomanufacturing site in Songdo, South Korea. The contract spans an impressive timeframe, extending through December 2037. With this latest addition, Samsung Biologics’ total accumulated contracts for 2024 surpass an astounding $3.3 billion. This phenomenal growth trajectory underscores the company’s unwavering commitment to meeting the evolving needs of the biopharmaceutical industry.
“We are thrilled to embark on this strategic collaboration with the Asia-based pharmaceutical company,” remarked John Rim, President and CEO of Samsung Biologics. “This deal arrives at a pivotal moment as we aggressively expand our biomanufacturing capacity to ensure the timely and efficient delivery of high-quality biopharmaceuticals to the global market. By leveraging our exceptional capabilities and proven expertise, we are committed to maintaining momentum for continued expansion. We aim to foster enduring and mutually beneficial partnerships with both existing and potential clients, ultimately driving growth and contributing to improved patient outcomes.”
Samsung Biologics’ unwavering commitment to excellence has earned it a prominent position within the global pharmaceutical landscape. To date, the company has forged partnerships with 17 of the world’s top 20 pharmaceutical companies, demonstrating its ability to cater to the most discerning clients. Moreover, Samsung Biologics continues to expand its global reach, extending its customer base to key regions, including Japan. In addition to existing sales offices in the U.S., the company is actively planning to establish a regional office in Tokyo, further strengthening its presence and relationships with clients in the region.
Samsung Biologics is dedicated to staying ahead of the curve in the ever-evolving world of biopharmaceutical manufacturing. The company is on track to finalize the construction of a dedicated antibody-drug conjugate (ADC) facility before the end of the current year. Furthermore, a fifth plant is poised to become operational in April 2025, adding a substantial capacity of 180 kL, bringing the total capacity across Plants 1-5 to an impressive 784 kL. This expansion will provide Samsung Biologics with the flexibility to effectively address the growing demand for biopharmaceutical manufacturing services.
Samsung Biologics remains deeply committed to innovating and developing cutting-edge solutions to address emerging health challenges and improve patient lives. The company continues to launch groundbreaking CDO platforms and implement state-of-the-art manufacturing technologies to support complex projects. This includes the development and production of multispecifics, a class of highly promising biotherapeutics with the potential to revolutionize the treatment of various diseases.
About Samsung Biologics Co., Ltd.
Samsung Biologics (KRX: 207940.KS) is a fully integrated, end-to-end CDMO service provider, offering a comprehensive suite of solutions for the development and manufacturing of biopharmaceutical products. The company’s services encompass everything from cell line development to final aseptic fill/finish, as well as laboratory testing support. Samsung Biologics operates state-of-the-art facilities that adhere to stringent CGMP (Current Good Manufacturing Practices) standards, featuring bioreactors ranging in size to accommodate diverse client needs.
To optimize operational efficiency and expand its capabilities in response to the escalating demand for biomanufacturing services, Samsung Biologics successfully completed Bio Campus I with Plant 4. This expansion boasts a combined total capacity of 604 kL. Recognizing the immense growth potential, Samsung Biologics has launched Bio Campus II, which includes the construction of Plant 5. This facility is scheduled to become operational in April 2025, adding an additional 180 kL of biomanufacturing capacity.
Samsung Biologics America serves as a vital extension of the company, allowing it to work in close proximity to clients based in the U.S. and Europe. The company is constantly investing in cutting-edge technologies to enhance its capabilities and meet the evolving needs of its clients. This includes investing in an antibody-drug conjugate (ADC) facility, a dedicated mRNA manufacturing facility, and expanding its aseptic filling capacity.
As a trusted and sustainable CDMO partner of choice, Samsung Biologics is dedicated to delivering on its commitments. The company is unwavering in its pursuit of on-time, in-full delivery of the products it manufactures, utilizing its flexible manufacturing solutions, operational excellence, and proven expertise to ensure customer satisfaction.
